^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MOv18 IgE

    i
    Other names: MOv18 IgE, MOv18
    Associations

    News

    Trials
    Company:
    Cancer Research UK, Epsilogen
    Drug class:
    Folate receptor 1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=45, Recruiting, Epsilogen Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MOv18 IgE
    3ms
    A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Epsilogen Ltd
    New P1 trial • Metastases
    |
    MOv18 IgE
    over1year
    Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. (PubMed, Nat Commun)
    The safety profile is tolerable and maximum tolerated dose has not been reached, with evidence of anti-tumour activity observed in a patient with ovarian cancer. These results demonstrate the potential of IgE therapy for cancer.
    P1 data • Journal • Metastases
    |
    FOLR1 ( Folate receptor alpha )
    |
    MOv18 IgE